SANJAY MATHEW to Piperazines
This is a "connection" page, showing publications SANJAY MATHEW has written about Piperazines.
Connection Strength
0.399
-
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66.
Score: 0.269
-
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9.
Score: 0.065
-
Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92.
Score: 0.064